Jan Kriska, MD
Sleep Medicine · Mount Airy, NCNPI 1104823327
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 316 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations.
Across 316 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Jazz Pharmaceuticals Inc.$810
- Avadel CNS Pharmaceuticals, LLC$410
- GSK$409
- Harmony Biosciences LLC$400
- Amgen$319
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,539100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $1,091 |
| Jazz Pharmaceuticals Inc. | 42 | $810 |
| Avadel CNS Pharmaceuticals, LLC | 19 | $410 |
| GSK | 31 | $409 |
| Harmony Biosciences LLC | 20 | $400 |
| Amgen | 21 | $319 |
| Novo Nordisk | 15 | $246 |
| Axsome Therapeutics, Inc. | 9 | $232 |
| Merck | 14 | $172 |
| Mylan Specialty L.p. | 10 | $160 |
| Pfizer | 8 | $160 |
| Boehringer Ingelheim | 9 | $146 |
| Lilly USA, LLC | 10 | $130 |
| Sanofi-aventis U.S. LLC | 6 | $112 |
| Novartis | 4 | $96 |
| Bayer | 4 | $65 |
| Sumitomo Pharma America, Inc. | 2 | $53 |
| Inspire Medical Systems, Inc. | 1 | $52 |
| Viatris Specialty LLC | 3 | $47 |
| Baxter Healthcare | 3 | $43 |
| Medtronic | 3 | $41 |
| Amarin Pharma, Inc. | 2 | $37 |
| Exact Sciences | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 3 | $28 |
| Johnson & Johnson | 2 | $28 |
| Astellas Pharma US Inc | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Advanced Respiratory, Inc | 2 | $25 |
| Philips North America LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Resmed Corp | 1 | $13 |
| AbbVie | 1 | $13 |
| Strongbridge US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMRYZ$122
How this compares
$5,539 in reported general payments places this provider in the 85th percentile of 52 sleep medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 19 | $214,236 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 181 | $162,672 |
| EliquisApixaban | 68 | $59,931 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 81 | $54,033 |
| OzempicSemaglutide | 47 | $53,604 |
| SunosiSolriamfetol Hcl | 43 | $37,150 |
| JardianceEmpagliflozin | 32 | $26,467 |
| Repatha SureclickEvolocumab | 29 | $26,283 |
| FarxigaDapagliflozin Propanediol | 25 | $24,925 |
| Armodafinil | 73 | $4,737 |
| VascepaIcosapent Ethyl | 20 | $4,559 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,943 |
| PaxlovidNirmatrelvir/Ritonavir | 16 | $2,858 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,796 |
| Modafinil | 94 | $2,519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $400 | $214,23619 claims |
| GSKTrelegy Ellipta | $409 | $162,672181 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,091 | $81,754117 claims |
| PfizerEliquis, Paxlovid | $160 | $62,78984 claims |
| Novo NordiskOzempic | $246 | $53,60447 claims |
| Axsome Therapeutics, Inc.Sunosi | $232 | $37,15043 claims |
| Boehringer IngelheimJardiance | $146 | $26,46732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 52 sleep medicine providers in North Carolina.
Other sleep medicine in Mount Airy
- Omavi BaileyFayetteville$246K
- Marjorie SoltisDurham$48K
- Douglas KirschCharlotte$26K
- Jamila BattleRaleigh$13K
- Daniel GarberConcord$6K
- Diana AlexandruGreenville$6K
- Cameron BarberCary$5K
- Pallavi ReddyBurlington$3K
- Jeannine GingrasCharlotte$3K
- Samuel BradshawGreensboro$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.